Legal Representation
Attorney
Joi A. White
USPTO Deadlines
Application History
48 events| Date | Code | Type | Description | Documents |
|---|---|---|---|---|
| Nov 24, 2025 | EISU | I | TEAS STATEMENT OF USE RECEIVED | Loading... |
| Aug 12, 2025 | EXRA | E | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED | Loading... |
| Aug 11, 2025 | EX5G | S | SOU EXTENSION 5 GRANTED | Loading... |
| May 14, 2025 | EXT5 | S | SOU EXTENSION 5 FILED | Loading... |
| May 14, 2025 | EXT5 | S | SOU EXTENSION 5 FILED | Loading... |
| May 14, 2025 | EEXT | I | SOU TEAS EXTENSION RECEIVED | Loading... |
| Oct 22, 2024 | EXRA | E | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED | Loading... |
| Oct 22, 2024 | EX4G | S | SOU EXTENSION 4 GRANTED | Loading... |
| Oct 22, 2024 | EXT4 | S | SOU EXTENSION 4 FILED | Loading... |
| Oct 22, 2024 | EEXT | I | SOU TEAS EXTENSION RECEIVED | Loading... |
| May 15, 2024 | EXRA | E | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED | Loading... |
| May 14, 2024 | EX3G | S | SOU EXTENSION 3 GRANTED | Loading... |
| May 14, 2024 | EXT3 | S | SOU EXTENSION 3 FILED | Loading... |
| May 14, 2024 | EEXT | I | SOU TEAS EXTENSION RECEIVED | Loading... |
| Nov 21, 2023 | EXRA | E | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED | Loading... |
| Nov 17, 2023 | EX2G | S | SOU EXTENSION 2 GRANTED | Loading... |
| Nov 17, 2023 | EXT2 | S | SOU EXTENSION 2 FILED | Loading... |
| Nov 17, 2023 | EEXT | I | SOU TEAS EXTENSION RECEIVED | Loading... |
| May 11, 2023 | EXRA | E | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED | Loading... |
| May 9, 2023 | EX1G | S | SOU EXTENSION 1 GRANTED | Loading... |
| May 9, 2023 | EXT1 | S | SOU EXTENSION 1 FILED | Loading... |
| May 9, 2023 | EEXT | I | SOU TEAS EXTENSION RECEIVED | Loading... |
| Nov 22, 2022 | NOAM | E | NOA E-MAILED - SOU REQUIRED FROM APPLICANT | Loading... |
| Sep 27, 2022 | NPUB | E | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED | Loading... |
| Sep 27, 2022 | PUBO | A | PUBLISHED FOR OPPOSITION | Loading... |
| Sep 7, 2022 | NONP | E | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED | Loading... |
| Aug 18, 2022 | CNSA | P | APPROVED FOR PUB - PRINCIPAL REGISTER | Loading... |
| Aug 18, 2022 | TEME | I | TEAS/EMAIL CORRESPONDENCE ENTERED | Loading... |
| Aug 17, 2022 | CRFA | I | CORRESPONDENCE RECEIVED IN LAW OFFICE | Loading... |
| Aug 17, 2022 | TROA | I | TEAS RESPONSE TO OFFICE ACTION RECEIVED | Loading... |
| Jul 13, 2022 | TCCA | I | TEAS CHANGE OF CORRESPONDENCE RECEIVED | Loading... |
| Jul 13, 2022 | ARAA | I | ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED | Loading... |
| Jul 13, 2022 | REAP | I | TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED | Loading... |
| May 22, 2022 | GNRN | O | NOTIFICATION OF NON-FINAL ACTION E-MAILED | Loading... |
| May 22, 2022 | GNRT | O | NON-FINAL ACTION E-MAILED | Loading... |
| May 22, 2022 | CNRT | R | NON-FINAL ACTION WRITTEN | Loading... |
| Apr 6, 2022 | ZZZX | Z | PREVIOUS ALLOWANCE COUNT WITHDRAWN | Loading... |
| Mar 8, 2022 | PBCR | Z | WITHDRAWN FROM PUB - OG REVIEW QUERY | Loading... |
| Feb 19, 2022 | CNSA | P | APPROVED FOR PUB - PRINCIPAL REGISTER | Loading... |
| Feb 18, 2022 | TEME | I | TEAS/EMAIL CORRESPONDENCE ENTERED | Loading... |
| Feb 17, 2022 | CRFA | I | CORRESPONDENCE RECEIVED IN LAW OFFICE | Loading... |
| Feb 17, 2022 | TROA | I | TEAS RESPONSE TO OFFICE ACTION RECEIVED | Loading... |
| Aug 18, 2021 | GNRN | O | NOTIFICATION OF NON-FINAL ACTION E-MAILED | Loading... |
| Aug 18, 2021 | GNRT | F | NON-FINAL ACTION E-MAILED | Loading... |
| Aug 18, 2021 | CNRT | R | NON-FINAL ACTION WRITTEN | Loading... |
| May 28, 2021 | DOCK | D | ASSIGNED TO EXAMINER | Loading... |
| Feb 16, 2021 | NWOS | I | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED | Loading... |
| Dec 12, 2020 | NWAP | I | NEW APPLICATION ENTERED | Loading... |
Detailed Classifications
Class 005
pharmaceutical products for the treatment and prevention of cancer and inflammatory diseases; therapeutic targets, namely, proteins or protein complexes, for the treatment and prevention of cancer, inflammation and inflammatory diseases; therapeutic cells, therapeutic proteins and therapeutic antibodies for human use for the treatment and prevention of cancer, inflammation and inflammatory diseases; therapeutics and cell therapies in the nature of proteins and protein complexes for the treatment of cancer, inflammation, and inflammatory diseases; engineered cell therapies in the nature of proteins and protein complexes for medical purposes, namely, the treatment and prevention of cancer, inflammation and inflammatory diseases; engineered cell therapy platforms consisting of modified cells, cell receptors, proteins and protein complexes; cell platforms consisting of modified cells, cell receptors, proteins and protein complexes for the treatment and prevention of cancer, inflammation and inflammatory diseases; biological technology platforms consisting of modified cells, cell receptors, proteins and protein complexes for developing and engineering therapeutic cells, therapeutic proteins, therapeutic antibodies, therapeutics and cellular therapies for the treatment and prevention of cancer, inflammation, and inflammatory diseases; cell platform consisting of modified cells, cell receptors, proteins and protein complexes for autologous and allogeneic cell manufacturing; therapeutics and cell therapies in the nature of proteins and protein complexes targeting targets lost in tumors for the treatment and prevention of cancer, inflammation and inflammatory diseases; gene therapy products, namely, genetically engineered tissues for transplant purposes
Class 040
custom manufacturing of cells, therapeutics and cell therapies for the treatment and prevention of cancer, inflammation and inflammatory diseases; biomanufacturing for others, namely, manufacturing of cells, therapeutics and cell therapeies for the treatment and prevention of cancer, inflammation and inflammatory diseases using biological cells in the manufacturing process; cell therapy manufacturing for others; autologous and allogeneic cell manufacturing for others; manufacturing services for others in the fields of therapeutics, cell therapies, biologics, medicine, and pharmaceuticals; providing technical information in the field of pharmaceutical manufacturing; custom manufacturing of biological cells, proteins, and antibodies for others for treatment and prevention of cancer, inflammation and inflammatory disease
Class 042
Identification and development of, therapeutic targets, namely, proteins and protein complexes, for others for the treatment and prevention of cancer, inflammation and inflammatory diseases; development of therapeutics and cell therapies for the treatment and prevention of cancer, inflammation, and inflammatory diseases; development of therapeutics and cell therapies targeting targets lost in tumors for the treatment and prevention of cancer, inflammation and inflammatory diseases; biotechnology research, development, testing and analysis for the treatment of cancer, inflammation, and inflammatory diseases; scientific research and development services; providing scientific information in the fields of treatment and prevention of cancer, inflammation and inflammatory diseases; research, development, engineering and testing services in the fields of therapeutics, cell therapies, biologics, medicine, and pharmaceuticals; medical laboratory services, namely, tissue material processing and analysis in the field of autologous and allogeneic biologic preparations for medical use; biotechnology laboratory services; scientific and medical laboratory services; genetic engineering services; engineering of biological cells, cellular targets, proteins, and antibodies for others
Classification
International Classes
005
040
042